Form 4: Cytek Biosciences Executive Awarded Stock Options and Restricted Stock Units

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, receives stock options and restricted stock units as part of her compensation.

Summary

• Valerie Barnett, Chief Legal Officer of Cytek Biosciences, was granted stock options to purchase 275,735 shares of common stock at an exercise price of $4.31 on March 4, 2025.
• These options vest over four years, starting with 1/48th of the shares vesting on April 4, 2025, and continuing monthly thereafter.
• Barnett also received 174,013 restricted stock units (RSUs), each representing a contingent right to receive one share of Cytek Biosciences common stock.
• These RSUs vest over four years, with varying portions vesting on May 18, August 18, November 18, and March 10 of each year, starting in 2025 and 2026 respectively.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Legal Officer.

Future Outlook

This document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedules are designed to incentivize long-term performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• The vesting schedules for both the options and RSUs are typical, designed to retain the executive over a multi-year period.
• Comparable companies such as Berkeley Lights, Inc. and 10x Genomics also utilize stock options and RSUs as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates